The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Professor Eduard Montanya is Professor of Medicine at the University of Barcelona, Head of the Diabetes Section at Bellvitge University Hospital, and Coordinator of the Diabetes and Metabolism Research Program at Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. He is the Scientific Director of the Spanish Network of Biomedical Research Centers in Diabetes and Associated Metabolic Diseases (CIBERDEM).
Professor Montanya’s main research interests are the regulation of beta-cell mass, cell therapy and regenerative medicine, and new drug therapies in diabetes. He has been Chair of the Islet Study Group of the Spanish Diabetes Association, President of the Catalan Diabetes Association, Secretary of the Islet Study group of the European Association for the Study of Diabetes, ad-hoc member of the Scientific Committee of European Union Innovative Medicines Initiative (IMI2 JU) and President of the Diabetes Advisory Council of the Health Department of Catalonia.